• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

糖尿病中的微量白蛋白尿:关注心血管和肾脏风险的降低

Microalbuminuria in diabetes: focus on cardiovascular and renal risk reduction.

作者信息

Bakris George L, Sowers James R

机构信息

Rush University Hypertension Center, Department of Preventive Medicine, Rush Presbyterian/St. Luke's Medical Center, 1700 W. Van Buren Street, Suite 470, Chicago, IL 60612, USA.

出版信息

Curr Diab Rep. 2002 Jun;2(3):258-62. doi: 10.1007/s11892-002-0092-4.

DOI:10.1007/s11892-002-0092-4
PMID:12643182
Abstract

Albuminuria has long been recognized as a harbinger for the progression of diabetic nephropathy. Recently, it has become increasingly recognized that albuminuria is a powerful risk factor for cardiovascular disease and stroke. In this article we explore evidence for albuminuria being an integral component of the cardiometabolic syndrome and a risk factor for cardiovascular disease and stroke.

摘要

长期以来,蛋白尿一直被视为糖尿病肾病进展的先兆。最近,人们越来越认识到蛋白尿是心血管疾病和中风的一个强大风险因素。在本文中,我们探讨了蛋白尿作为心脏代谢综合征的一个组成部分以及心血管疾病和中风风险因素的证据。

相似文献

1
Microalbuminuria in diabetes: focus on cardiovascular and renal risk reduction.糖尿病中的微量白蛋白尿:关注心血管和肾脏风险的降低
Curr Diab Rep. 2002 Jun;2(3):258-62. doi: 10.1007/s11892-002-0092-4.
2
[Antihypertensive treatment in type II diabetes and diabetic nephropathy].[2型糖尿病和糖尿病肾病的降压治疗]
Nephrologie. 2000;21(2):47-55.
3
Elevated levels of plasma von Willebrand factor and the risk of macro- and microvascular disease in type 2 diabetic patients with microalbuminuria.2型糖尿病合并微量白蛋白尿患者血浆血管性血友病因子水平升高与大血管和微血管疾病风险
Nephrol Dial Transplant. 2001 Oct;16(10):2028-33. doi: 10.1093/ndt/16.10.2028.
4
Microalbuminuria as a target to improve cardiovascular and renal outcomes.微量白蛋白尿作为改善心血管和肾脏预后的靶点。
Am J Kidney Dis. 2006 Jun;47(6):927-46. doi: 10.1053/j.ajkd.2006.02.182.
5
Microalbuminuria: is it a valid predictor of cardiovascular risk?微量白蛋白尿:它是心血管风险的有效预测指标吗?
Cleve Clin J Med. 2003 Mar;70(3):255-61. doi: 10.3949/ccjm.70.3.255.
6
Microalbuminuria, clinical nephropathy and hypertension in diabetes.
J Hum Hypertens. 1991 Aug;5(4):255-63.
7
Antihypertensive therapy in patients with type 2 diabetes mellitus: focus on nephropathy.
Adv Nephrol Necker Hosp. 1999;29:241-55.
8
Microalbuminuria: a marker to increased renal and cardiovascular risk in diabetes mellitus.微量白蛋白尿:糖尿病患者肾脏和心血管疾病风险增加的一个标志物。
Scott Med J. 1997 Aug;42(4):99-104. doi: 10.1177/003693309704200401.
9
[Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes].[厄贝沙坦对2型糖尿病患者糖尿病肾病进展的影响]
Ugeskr Laeger. 2001 Oct 1;163(40):5519-24.
10
Microalbuminuria as a marker of cardiovascular and renal risk in type 2 diabetes mellitus: a temporal perspective.微量白蛋白尿作为2型糖尿病心血管和肾脏风险的标志物:时间角度的探讨
Am J Physiol Renal Physiol. 2004 Mar;286(3):F442-50. doi: 10.1152/ajprenal.00247.2003.

引用本文的文献

1
Connective tissue growth factor and susceptibility to renal and vascular disease risk in type 1 diabetes.结缔组织生长因子与1型糖尿病患者发生肾脏和血管疾病风险的易感性
J Clin Endocrinol Metab. 2008 May;93(5):1893-900. doi: 10.1210/jc.2007-2544. Epub 2008 Mar 4.
2
Diabetes, hypertension, and cardiovascular derangements: pathophysiology and management.糖尿病、高血压与心血管紊乱:病理生理学与管理
Curr Hypertens Rep. 2004 Jun;6(3):215-23. doi: 10.1007/s11906-004-0072-y.

本文引用的文献

1
American Diabetes Association: clinical practice recommendations 2002.美国糖尿病协会:2002年临床实践建议
Diabetes Care. 2002 Jan;25 Suppl 1:S1-147. doi: 10.2337/diacare.25.2007.s1.
2
Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data.血管紧张素转换酶抑制剂与非糖尿病肾病的进展。患者水平数据的荟萃分析。
Ann Intern Med. 2001 Jul 17;135(2):73-87. doi: 10.7326/0003-4819-135-2-200107170-00007.
3
Microalbuminuria: what is it? Why is it important? What should be done about it?
微量白蛋白尿:它是什么?为什么它很重要?对此应该怎么做?
J Clin Hypertens (Greenwich). 2001 Mar-Apr;3(2):99-102. doi: 10.1111/j.1524-6175.2001.00442.x.
4
Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial.雷米普利与氨氯地平对高血压性肾硬化症肾脏结局的影响:一项随机对照试验。
JAMA. 2001 Jun 6;285(21):2719-28. doi: 10.1001/jama.285.21.2719.
5
Diabetes, hypertension, and cardiovascular disease: an update.糖尿病、高血压与心血管疾病:最新进展
Hypertension. 2001 Apr;37(4):1053-9. doi: 10.1161/01.hyp.37.4.1053.
6
Elevated urinary albumin excretion is associated with impaired arterial dilatory capacity in clinically healthy subjects.在临床健康受试者中,尿白蛋白排泄增加与动脉扩张能力受损有关。
Circulation. 2001 Apr 10;103(14):1869-74. doi: 10.1161/01.cir.103.14.1869.
7
Insulin resistance and cardiovascular disease.胰岛素抵抗与心血管疾病。
J Clin Endocrinol Metab. 2001 Feb;86(2):713-8. doi: 10.1210/jcem.86.2.7202.
8
Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration.血管紧张素转换酶抑制剂、钙拮抗剂及其他降压药物的作用:前瞻性设计的随机试验综述结果。降压治疗试验协作组
Lancet. 2000 Dec 9;356(9246):1955-64. doi: 10.1016/s0140-6736(00)03307-9.
9
Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group.在患有高血压和糖尿病的成年人中保护肾功能:一种共识方法。美国国家肾脏基金会高血压和糖尿病执行委员会工作组。
Am J Kidney Dis. 2000 Sep;36(3):646-61. doi: 10.1053/ajkd.2000.16225.
10
Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo.醛固酮在体内调节纤溶酶原激活物抑制剂-1和肾小球硬化。
Kidney Int. 2000 Sep;58(3):1219-27. doi: 10.1046/j.1523-1755.2000.00277.x.